NCT07102381View on ClinicalTrials.gov

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 24, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

August 1, 2030

Conditions
HER2-positive Breast CancerBreast Cancer
Interventions
DRUG

Zanidatamab

Administered intravenously (IV)

DRUG

Paclitaxel

Administered intravenously (IV)

DRUG

Docetaxel

Administered intravenously (IV)

DRUG

Carboplatin

Administered intravenously (IV)

DRUG

Trastuzumab

Administered intravenously (IV)

DRUG

Pertuzumab

Administered intravenously (IV)

Trial Locations (10)

19713

RECRUITING

Medical Oncology Hematology Associates, Newark

20707

RECRUITING

Maryland Oncology Hematology, Laurel

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

22601

RECRUITING

Shenandoah Oncology, Winchester

23502

RECRUITING

Virginia Oncology Associates, Norfolk

37203

RECRUITING

Sarah Cannon Research Institute (Nashville), Nashville

75246

RECRUITING

Texas Oncology DFW, Dallas

77024

RECRUITING

Texas Oncology Gulf Coast, Houston

80218

RECRUITING

Rocky Mountain Cancer Centers, Denver

98648

RECRUITING

Northwest Cancer Specialists, Vancouver

Sponsors
All Listed Sponsors
collaborator

Jazz Pharmaceuticals Ireland Limited

INDUSTRY

lead

Jazz Pharmaceuticals

INDUSTRY

NCT07102381 - A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter